APA

Jastrzebskal M., Widecka K., Naruszewicz M., Ciechanowicz A., Janczak-Bazan A., Foltynska A., Goracy I., Chetstowski K. & Wesotowska T. (20050421). Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. : Nutrition, metabolism, and cardiovascular diseases : NMCD.

Chicago

Jastrzebskal M, Widecka K, Naruszewicz M, Ciechanowicz A, Janczak-Bazan A, Foltynska A, Goracy I, Chetstowski K and Wesotowska T. 20050421. Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. : Nutrition, metabolism, and cardiovascular diseases : NMCD.

Harvard

Jastrzebskal M., Widecka K., Naruszewicz M., Ciechanowicz A., Janczak-Bazan A., Foltynska A., Goracy I., Chetstowski K. and Wesotowska T. (20050421). Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. : Nutrition, metabolism, and cardiovascular diseases : NMCD.

MLA

Jastrzebskal M, Widecka K, Naruszewicz M, Ciechanowicz A, Janczak-Bazan A, Foltynska A, Goracy I, Chetstowski K and Wesotowska T. Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. : Nutrition, metabolism, and cardiovascular diseases : NMCD. 20050421.